Sunar, NebahatSizer, MulaimGunsel, HamdinTekes, Guelten CirkinDonmez, Dicle AkkilicIcen, Mehmet Sait2025-02-222025-02-2220242667-663Xhttps://doi.org/10.4328/ACAM.22186https://hdl.handle.net/11468/29521Aim: Investigate the relationship between gestational thrombocytopenia (GT) and adverse maternal and fetal outcomes in pregnant women. Material and Methods: 97 patients who were diagnosed with gestational thrombocytopenia during pregnancy, had no other disease that causes thrombocytopenia and delivered in our clinic were included in the study. The patients were divided into two groups according to their platelet values. Group-1 platelet count was <70.000/mm3 and Group-2 platelet count was 70.000- 150.000/mm3. In the analysis of negative perinatal outcomes, logistic regression analysis was performed. P <0.05 was considered significant in the analysis results. Results: From the laboratory data of the patients diagnosed with gestational thrombocytopenia, the mean platelet count was 85.28 +/- 27.08 (min -max: 22-142) and mean hematocrit was 35.91 +/- 3.63 (min -max: 21-45). When the groups were evaluated considering their hematocrit values; the mean hematocrit value of the patients in Group-2 (36.42 +/- 3.22) was higher than the mean hematocrit value (34.26 +/- 4.39) of the patients in Group-1, and a significant difference was found between them (p:0.03). This significant difference was also present when the platelet value was taken as the limit of 110,000 (p:0.039). Discussion: Apgar scores are lower in patients diagnosed with gestational thrombocytopenia and with platelet values below 70,000, and the need for blood transfusion (erythrocyte suspension, FFP (Fresh Frozen Plasma) and platelet product) is higher. The need for erythrocyte transfusion continues even when the platelet limit is 80,000, and the need for platelet transfusion is 100,000.eninfo:eu-repo/semantics/openAccessGestational ThrombocytopeniaPregnancyAdverse Maternal and Fetal OutcomesArticle156439443WOS:00124476930001410.4328/ACAM.22186